Esmat Samia M, Hegazy Rehab A, Gawdat Heba I, Abdel Hay Rania M, Allam Riham S, El Naggar Rofaida, Moneib Hoda
Faculty of Medicine, Department of Dermatology, Cairo University, Cairo, Egypt.
Faculty of Medicine, Department of Ophthalmology, Cairo University, Cairo, Egypt.
Lasers Surg Med. 2017 Nov;49(9):835-843. doi: 10.1002/lsm.22684. Epub 2017 May 10.
Female pattern hair loss (FPHL) is the most common form of hair loss in women. Nevertheless, its management represents a real challenge. Among the FDA approved therapeutic modalities for FPHL are topical minoxidil and more recently low-level light therapy (LLLT).
Assess the efficacy and safety of LLLT in comparison to topical minoxidil 5% and to a combination of both therapies in the treatment of FPHL.
This study included 45 female patients with proven FPHL. They were randomly divided into three equal groups, where group (i) patients were instructed to apply topical minoxidil 5% twice daily, group (ii) patients received LLLT using the helmet iGrow® device for 25 minutes 3 days weekly, and group (iii) patients received a combination of both topical minoxidil 5% twice daily and LLLT for 25 minutes 3 days weekly for 4 months (study duration). Evaluation was done according to clinical, dermoscopic (folliscopic), and ultrasound bio-microscopic (UBM) parameters. Patient satisfaction and side effects were reported.
The efficacy and safety of both topical minoxidil and LLLT were highlighted with comparable results in all parameters. The combination group (iii) occupied the top position regarding Ludwig classification and patient satisfaction. UBM and dermoscopic findings showed significant increase in the number of regrowing hair follicles at 4 months in all groups, whereas only UBM showed such significant increase at 2 months in the combination group (iii). A non-significant increase in the hair diameter was also documented in the three groups.
LLLT is an effective and safe tool with comparable results to minoxidil 5% in the treatment of FPHL. Owing to the significantly better results of combination therapy, its usage is recommended to hasten hair regrowth. Lasers Surg. Med. 49:835-843, 2017. © 2017 Wiley Periodicals, Inc.
女性型脱发(FPHL)是女性最常见的脱发形式。然而,其治疗是一项真正的挑战。美国食品药品监督管理局(FDA)批准的用于FPHL的治疗方法包括局部使用米诺地尔,以及最近的低能量激光疗法(LLLT)。
评估LLLT与5%局部米诺地尔以及两种疗法联合使用治疗FPHL的疗效和安全性。
本研究纳入45例确诊为FPHL的女性患者。她们被随机分为三组,其中第(i)组患者被指示每天两次外用5%米诺地尔,第(ii)组患者使用iGrow®头盔接受LLLT治疗,每周3天,每次25分钟,第(iii)组患者每天两次外用5%米诺地尔并每周3天、每次25分钟接受LLLT治疗,持续4个月(研究持续时间)。根据临床、皮肤镜(毛囊镜)和超声生物显微镜(UBM)参数进行评估。报告患者满意度和副作用。
局部米诺地尔和LLLT的疗效和安全性在所有参数中均得到凸显,结果相当。联合治疗组(iii)在路德维希分类和患者满意度方面占据首位。UBM和皮肤镜检查结果显示,所有组在4个月时再生毛囊数量显著增加,而只有联合治疗组(iii)在2个月时通过UBM显示出这种显著增加。三组的毛发直径也有不显著的增加。
LLLT是一种有效且安全的治疗工具,在治疗FPHL方面与5%米诺地尔效果相当。由于联合治疗效果明显更好,建议使用联合治疗以加速头发生长。《激光外科学与医学》49:835 - 843, 2017。© 2017威利期刊公司